Skip to content
Review

Targeting the choroidal neovascularization microenvironment: new perspectives in nanotherapeutic strategies.

Sep 2026 · European journal of pharmaceutics and biopharmaceutics · pp. 115238 · 0 citations · 157 references
Medicine

TL;DR

An in-depth exploration of advanced nano-therapeutic strategies designed to multi-target angiogenic pathways, dynamically manipulate reactive oxygen species, disrupt hypoxia-driven feedback loops, reprogram the immunoinflammatory network, and restore defective cellular autophagy are provided.

Abstract

Choroidal neovascularization (CNV) is a key pathological mechanism underlying irreversible vision loss in diseases such as age-related macular degeneration (AMD). Although anti-vascular endothelial growth factor (VEGF) therapies effectively inhibit angiogenesis, they are limited by the need for frequent injections, the tendency to induce resistance, and their inability to reverse the complex pathological microenvironment driving CNV. Research indicates that the initiation and progression of CNV are cooperatively driven by the local microenvironment, particularly through the interplay of oxidative stress, hypoxia, and inflammatory networks. In recent years, the emergence of nanotechnology has provided unprecedented tools for precise modulation of this microenvironment. This review systematically delineates the mechanisms of CNV formation, with a focused analysis on the core interplay between oxidative stress, hypoxia, and inflammation. We provide an in-depth exploration of advanced nano-therapeutic strategies designed to multi-target angiogenic pathways, dynamically manipulate reactive oxygen species, disrupt hypoxia-driven feedback loops, reprogram the immunoinflammatory network, and restore defective cellular autophagy. This review aims to provide a theoretical foundation and forward-looking perspective for developing next-generation microenvironment-targeted therapies capable of intervening in CNV.

View source

Similar papers

Review Open access Sep 2026

Hypoxia-inducible factor as a master switch in ocular neovascularization: overcoming anti-VEGF resistance and exploring therapeutic prospects

Hypoxia-inducible factor (HIF) is a key driver of ocular neovascular diseases. We systematically discuss its regulatory mechanisms and pathological roles in diabetic retinopathy (DR), retinopathy of prematurity (ROP), and neovascular age-related macular degeneration (nAMD). Upon integration of diverse upstream stimul...

Teng Liu, Yi-Fei He, Yi-Fan Liao et al. · 0 citations
Review Open access Sep 2026

Engineering Microenvironment-Responsive Nanobiomaterials for Precision Therapy of Fundus Neovascular Diseases

Fundus neovascular diseases (FNDs) cause irreversible visual impairment through pathological angiogenesis, vascular leakage, inflammation, oxidative injury, and barrier breakdown. Current anti-vascular endothelial growth factor (VEGF) therapy has greatly improved disease control, but repeated intraocular injections,...

Wen-Tao Xuan, Peng-Li Zhang, Xue-Hua Ma et al. · 0 citations
Open access Sep 2026

Cornea-Penetrating Nanodrug Co-Delivering VEGF-Silencing siRNA and Lutein for Treating Age-Related Macular Degeneration.

A noninvasive, cornea-penetrating nanodrug based on chitosan-modified lipid-polymer hybrid nanoparticles (LPNPs) for co-delivery of lutein and VEGF-silencing siRNA (Chi@Lu/si NPs) to treat AMD, which interrupts the pathological cycle driving CNV progression.

Yong Li, Fan Xiao, Zi-Wei Liu et al. · 0 citations
Review Open access Aug 2026

Targeting angiogenesis: advances in the design and engineered applications of nanobodies

By overcoming key limitations of conventional antibodies, engineered nanobodies open new avenues for precise, multi-dimensional interventions in solid tumors and highlight the value of engineered Nbs as a highly programmable and transformative platform.

Yuxuan Liu, Zhao-Hai Li, Yuan-Yuan Ma et al. · 0 citations
Open access Aug 2026

MicroRNA-34a suppresses KLF2 to promote pathological angiogenesis through the CXCR4/CXCL12 pathway in age-related macular degeneration.

A causal link between the age-related miR-34a and neovascularization in AMD is established and miR-34a directly targets and inhibits the transcription factor KLF2, thereby upregulating the proangiogenic factors CXCR4 and CXCL12.

Jason J. Colasanti, A. Santeford, Joseph B. Lin et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.